

11-310-C100

## Monoclonal Antibody to CD72 Purified Antibody (0.1 mg)

Clone:	3F3
lsotype:	Mouse IgG2b
Specificity:	The antibody 3F3 reacts with CD72, a 39-43 kDa type II membrane glycoprotein (C-type lectin family). CD72 is a pan-B cell marker expressed throughout the B lymphocytes diferentiation with the exception of plasma cells; it is also present on follicular dendritic cells. HLDA V; WS Code B CD72.5 HLDA VI; WS Code B CD72.1 HLDA VI; WS Code 6 BP 84
<b>Regulatory Status:</b>	RUO
Immunogen:	Normal human lymphocytes from a lymph node.
Species Reactivity:	Human
Application:	Flow Cytometry Recommended dilution:1 µg/ml Immunoprecipitation
Purity:	> 95% (by SDS-PAGE)
Purification:	Purified by precipitation and chromatography
Concentration:	1 mg/ml
Storage Buffer:	Phosphate buffered saline (PBS) with 15 mM sodium azide, approx. pH 7.4
Storage / Stability:	Store at 2-8°C. Do not freeze. Do not use after expiration date stamped on vial label.
Expiration:	See vial label
Lot Number:	See vial label
Background:	CD72 is a transmembrane glycoprotein expressed as a homodimer especially in B cells, but also in other antigen presenting cells such as dendritic cells and macrophages. Through one of its immunoreceptor tyrosine-based inhibitory motives (ITIMs), CD72 interacts with tyrosine phosphatase SHP-1, thereby suppressing B cell responsiveness. Binding of CD72 with its ligand CD100 (Sema4D) prevents BCR association and phosphorylation of CD72 and results in dissociation of SHP-1 from CD72, thus enables B cell activation.

For laboratory research only, not for drug, diagnostic or other use.



References:

\*Kumanogoh A, Watanabe C, Lee I, Wang X, Shi W, Araki H, Hirata H, Iwahori K, Uchida J, Yasui T, Matsumoto M, Yoshida K, Yakura H, Pan C, Parnes JR, Kikutani H: Identification of CD72 as a lymphocyte receptor for the class IV semaphorin CD100: a novel mechanism for regulating B cell signaling. Immunity. 2000 Nov;13(5):621-31.

\*Kumanogoh A, Kikutani H: The CD100-CD72 interaction: a novel mechanism of immune regulation. Trends Immunol. 2001 Dec;22(12):670-6.

\*Kumanogoh A, Shikina T, Watanabe C, Takegahara N, Suzuki K, Yamamoto M, Takamatsu H, Prasad DV, Mizui M, Toyofuku T, Tamura M, Watanabe D, Parnes JR, Kikutani H. Requirement for CD100-CD72 interactions in fine-tuning of B-cell antigen receptor signaling and homeostatic maintenance of the B-cell compartment. Int Immunol. 2005 Oct;17(10):1277-82.

\*Mizrahi S, Markel G, Porgador A, Bushkin Y, Mandelboim O: CD100 on NK cells enhance IFNgamma secretion and killing of target cells expressing CD72. PLoS ONE. 2007 Sep 5;2(9):e818.

\*Leukocyte Typing V., Schlossman S. et al. (Eds.), Oxford University Press (1995). \*Leukocyte Typing VI., Kishimoto T. et al. (Eds.), Garland Publishing Inc. (1997).

\*Mizrahi S, Markel G, Porgador A, Bushkin Y, Mandelboim O: CD100 on NK cells enhance IFNgamma secretion and killing of target cells expressing CD72. PLoS One. 2007 Sep 5;2(9):e818.

\*Dauby N, Kummert C, Lecomte S, Liesnard C, Delforge ML, Donner C, Marchant A: Primary Human Cytomegalovirus Infection Induces the Expansion of Virus-Specific Activated and Atypical Memory B Cells. J Infect Dis. 2014 May 1. pii: jiu255. [Epub ahead of print]

\*Kanderova V, Kuzilkova D, Stuchly J, Vaskova M, Brdicka T, Fiser K, Hrusak O, Lund-Johansen F, Kalina T: High-resolution Antibody Array Analysis of Childhood Acute Leukemia Cells. Mol Cell Proteomics. 2016 Apr;15(4):1246-61.

Unless indicated otherwise, all products are For Research Use Only and not for diagnostic or therapeutic use. Not for resale or transfer either as a stand-alone product or as a component of another product without written consent of EXBIO. EXBIO will not be held responsible for patent infringement or other violations that may occur with the use of our products. All orders are accepted subject to EXBIO's term and conditions which are available at www.exbio.cz.

For laboratory research only, not for drug, diagnostic or other use.